# **SBI Life Insurance (SBILIF)**

CMP: ₹ 1140 Target: ₹ 1350 (18%) Target Period: 12 months

April 27, 2023

Others

10.9



**BUY** 

ICICI direct

| Particulars           |                |
|-----------------------|----------------|
| Particulars           | Amount         |
| Market Capitalisation | ₹ 114142 crore |
| EV (as on Mar 23)     | ₹ 42410 crore  |
| AUM                   | ₹ 307340 crore |
| 52 week H/L           | 1339/1003      |
| Face value            | ₹ 10           |


#### Shareholding pattern Mar'22 Jun'22 Sept'22 Dec'22 Mar'23 Promoter 55.5 55.5 55.5 55.5 55.5 FII 21.2 23.9 24.3 25.1 25.1 ΠII 12.5 12.3 15.7 14.9 15.1

8.3

4.6

4.5

4.3



## Risk to our call

- Private market share based on IRP at 22.3%
- Key Risk: 1) Adverse change in commercial relation with parent; 2) Slower business growth

## **Research Analyst**

Kaial Gandhi kajal.gandhi@icicisecurities.com

Vishal Narnolia vishal.narnolia@icicisecurities.com

pravin.Mule@icicisecurities.com

# Balanced growth to drive VNB growth ahead

About the stock: SBI Life (SBIL) is among the most dominant players in the Indian life insurance industry with strong distribution network, parentage, operating metrics.

- Balanced product mix with focus on opex ratio ahead of industry
- Strong parentage led distribution remains key catalyst

Q4FY23 Results: Premium accretion slower than expected

- Gross premium growth slower at 14% YoY; NBP growth up 21%, led by tax amendment
- VNB margins steady at 30.1%, aided by balanced product mix
- Surplus at ₹ 1942 crore; focus on cost and decline in claims led PAT growth at 16% YoY to ₹ 777 crore
- AUM growth decent at 16% YoY to ₹ 307340 crore

What should investors do? SBIL's share price has grown ~45% in the past three years. Lower proportion of high ticket business, strong distribution and diversified product mix along with lowest cost on relative basis is seen aiding business growth as well VNB margin. The stock is reasonably priced and is currently trading at 1.9x FY25E embedded value.

We retain our BUY rating on the stock

Target Price & Valuation: We broadly maintain our EV estimates for FY24-25E. We upgrade out target price for SBIL from ₹ 1300 to ₹ 1350, valuing the stock at 2.2x FY25E EV.

#### Key triggers for future price performance:

- Recent amendment in taxation is not seen having a substantial impact on growth momentum. Continued traction anticipated in non-par business. Focus on annuity and protection segment to further aid growth
- Continued distribution moat in terms of banca partnership (with parent), new digital, banca partnerships and strong agency force to aid business growth
- Continue to deliver cost efficiency. Any increase in commission (new EOM guidelines) is not seen having any substantial impact on VNB trajectory

Alternate Stock Idea: Apart from SBIL, in our coverage we also like Star Health.

- Market leader in retail health insurance segment (~33% market share) with potential for sustained business growth and, thus, earnings trajectory
- BUY with a target price of ₹ 650

#### Key Financial Summary 2 year CAGR 3 year CAGR FY21 (₹ Crore) FY20 **FY22** FY23 FY24E FY25E (FY20-FY23) (FY23-25E) New business premium 16592.5 20624.2 24576.9 30428.8 22% 33811.6 40772.6 16% APE 10505.2 11366.7 13427.0 16687.9 17% 18663.6 22462.0 16% Total premium 40324.0 49768.3 58633.8 69535.5 20% 78710.3 91252.8 15% PAT 1422.2 1455.9 903.3 1232.5 -5% 1858.0 2125.1 31% EV 26290.0 33386.0 39264.9 45193.7 20% 51447.4 58784.5 14% P/E(x)80.2 78.3 75.7 66.3 61.4 53.6 P/BV (x) 13.0 11.0 9.8 8.8 8.3 7.3 P/IEV (x) 4.3 3.4 2.9 2.5 2.2 1.9 15.5 RoEV (%) 20.5 19.1 17.9 14.6 15.0

CDI Life FCC Disalesure Co.



# Key takeaways of recent quarter & conference call highlights

# Q4FY23 Results: Premium accretion slower. Lower opex, higher allocation to shareholders support earnings momentum

- SBI Life has posted premium accretion at 21% YoY at ₹ 19897 crore. New business premium growth came in relatively slower at 21% YoY at ₹ 8077 crore (-4% QoQ) despite anticipated higher traction amid tax amendment. Renewal premium is up 10% YoY at ₹ 11937 crore, with conservation ratio down ~200 bps YoY at ~81%. On annualised premium equivalent (APE basis), growth remained in single digits at 9% YoY in Q4FY23. On a FY23 basis, premium growth came in at 15% YoY with NBP growth at 16%
- Private market share based on rated individual premium maintained at 22.3% in FY23. VNB margin reported at 30.1% in FY23 (29.6% in 9MFY23) vs. 25.9% in FY22, led by change in product mix. In Q4FY23, non-par segment witnessed robust growth, group protection and annuity segment healthy momentum while individual protection de-grew on NBP basis
- AUM grew at a decent pace of 15% YoY to ₹ 307340 crore. Shareholders and policyholders (excluding linked liabilities) assets witnessed growth at ~13% and 17% YoY. Assets held in lieu of linked products rose ~17% YoY. Income from investment de-grew YoY at ₹ 1186 crore
- Commission ratio remained flat QoQ and increased ~50 bps YoY, to 4.4% in Q4FY23. Opex ratio increased 20 bps QoQ at 5%, though remained flat YoY. Consequently, total cost ratio increased ~20 bps QoQ at 9.4% in Q4FY23
- Lower cost and higher appropriation to shareholder fund offset slower premium growth resulting into a surplus of ₹ 1942 crore. Consequently, PAT increased 16% YoY at ₹ 777 crore

### Q4FY23 earnings conference call highlights

- SBI Life has maintained its leadership position in terms of number of policies.
  Individual new business sum assured grew 13% YoY vs. 12% growth of industry
- Non par guaranteed products registered robust growth of 116% YoY driven by business contribution of Smart Platina Plus product. Individual annuity business grew 134% YoY led by new business contribution of Smart Annuity Plus product
- During the quarter, Banca channel contributed 63% to Individual APE and non SBI banca partners (like Indian bank, Uco Bank, South Indian Bank, Yes Bank, Punjab & Sind Bank) had contributed ~3% to individual NBP. SBI Life has also signed corporate agency agreement with Karur Vysya Bank
- With healthy growth and change in product mix, the management expects to maintain healthy and sustainable VNB growth. APE growth guidance for FY24 continues to be in the range of 20-25% YoY. Margins are expected to remain in a similar range (~29-30%)
- In the last two to three years, product mix is moving towards the non-par business and yield curve is going up. Continue to focus on protection business. Ulip is also expected to witness strong growth in FY24E
- Credit life share in terms of APE was at ₹ 2000 crore in FY23 vs. ₹ 1700 crore in FY22

| ESG Disclosure Score |      |      |      |  |  |  |  |  |
|----------------------|------|------|------|--|--|--|--|--|
| Score                | FY20 | FY21 | FY22 |  |  |  |  |  |
| Environmental        | 1.6  | 1.6  | 2.5  |  |  |  |  |  |
| Social               | 30.9 | 30.9 | 30.9 |  |  |  |  |  |
| Governance           | 63.6 | 63.6 | 63.6 |  |  |  |  |  |
| Overall ESG Score    | 32.1 | 32.1 | 32.3 |  |  |  |  |  |

Source: Bloomberg; ICICI Direct Research \* score ranges from 0-100 with a high score

| Exhibit 1: Peer Con | nparis | on    |        |        |         |       |         |       |      |          |       |       |         |       |       |       |      |       |       |       |
|---------------------|--------|-------|--------|--------|---------|-------|---------|-------|------|----------|-------|-------|---------|-------|-------|-------|------|-------|-------|-------|
| Contan / Commons    | CMP    | M Cap |        |        | EPS (₹) |       | P/E (x) |       |      | P/EV (x) |       |       | RoE (%) |       |       |       |      |       |       |       |
| Sector / Company    | (₹)    | TP(₹) | Rating | (₹ bn) | FY22    | FY23E | FY24E   | FY25E | FY22 | FY23E    | FY24E | FY25E | FY22    | FY23E | FY24E | FY25E | FY22 | FY23E | FY24E | FY25E |
| SBI Life Insurance  | 1140   | 1350  | Buy    | 114    | 15.1    | 17.2  | 18.6    | 21.3  | 75.7 | 66.3     | 61.4  | 53.6  | 2.9     | 2.5   | 2.2   | 1.9   | 8.5  | 10.8  | 16.2  | 15.9  |
| HDFC Life           | 517    | 570   | Hold   | 111    | 5.7     | 6.4   | 7.3     | 8.7   | 90.4 | 80.6     | 70.9  | 59.2  | 3.6     | 2.8   | 2.4   | 2.0   | 18.0 | 18.1  | 18.2  | 18.2  |

|                               | Q4FY23   | Q4FY23E  | Q4FY22   | YoY (%) | Q3FY23   | QoQ (%) | Comments                                                              |
|-------------------------------|----------|----------|----------|---------|----------|---------|-----------------------------------------------------------------------|
| F' . V . D . '                |          |          |          |         |          | , ,     | Uptick in Q4FY23 premium led by tax amendment                         |
| First Year Premium            | 4,089.6  | 3,857.0  | 3,853.6  | 6.1     | 5,055.2  | -19.1   | . ,                                                                   |
| Renewal Premium               | 11,937.0 | 12,491.7 | 10,842.5 | 10.1    | 10,908.3 | 9.4     | Persistency remain steady                                             |
| Single Premium                | 3,986.9  | 3,949.5  | 2,812.4  | 41.8    | 3,368.4  | 18.4    |                                                                       |
| Net Premium income            | 19,897   | 19,518   | 17,434   | 14.1    | 19,171   | 3.8     |                                                                       |
| Income from Investments       | 1,186.1  | 7,389.0  | 2,999.5  | -60.5   | 7,443.0  | -84.1   |                                                                       |
| Total revenue                 | 22,805.4 | 26,926   | 21,427.9 | 6.4     | 26,626.7 | -14.4   |                                                                       |
| Commission                    | 871.4    | 917.3    | 677.9    | 28.6    | 845.2    | 3.1     | Commission ratio up $\sim\!50$ bps YoY to 4.4%                        |
| Operating expenses            | 1,001.8  | 1,014.9  | 872.5    | 14.8    | 913.9    | 9.6     | Opex ratio steady at 5%                                               |
| Management Expenses           | 1,873.2  | 1,932.2  | 1,550.4  | 20.8    | 1,759.1  | 6.5     |                                                                       |
| Benefits paid                 | 9,123.2  | 8,392.5  | 7,373.4  | 23.7    | 8,355.9  | 9.2     |                                                                       |
| Change in Actuarial Liability | 9,604.3  | 14,793.7 | 10,892.1 | -11.8   | 15,937.5 | -39.7   |                                                                       |
| Total Expenses                | 20,863.6 | 25,389.9 | 20,122.6 | 3.7     | 26,330.3 | -20.8   |                                                                       |
| Surplus/ (deficit)            | 1,941.8  | 1,536.6  | 1,305.3  | 48.8    | 296.4    | 555.1   | Healthy premium and lower actuarial liabilities led to higher surplus |
| Transfer to SH's A/c          | 2,302.8  | 1,600.0  | 1,471.2  | 56.5    | 113.8    | 1,923.7 | to higher outpluo                                                     |
| Transfer to SH's A/c          | 2,302.8  | 1,600.0  | 1,471.2  | 56.5    | 113.8    | 1,923.7 |                                                                       |
| Investment income             | 212.5    | 212.2    | 238.2    | -10.8   | 203.0    | 4.7     |                                                                       |
| Profit/ (loss) before tax     | 793.6    | 813.1    | 694.1    | 14.3    | 310.8    | 155.3   |                                                                       |
| PAT                           | 776.9    | 756.1    | 672.2    | 15.6    | 304.1    | 155.4   |                                                                       |
| Key Metrics                   |          |          |          |         |          |         |                                                                       |
| NBP                           | 8,076.5  | 7,806.5  | 6,666.0  | 21.2    | 8,423.6  | -4.1    | Individual non-par & annuity remain in focus                          |
| AUM                           | 3,07,340 |          | 2,67,410 | 14.9    | 2,99,990 | 2.5     | Decent growth on YoY basis                                            |

Source: Company, ICICI Direct Research

| Exhibit 3: Change in estin        | nates    |          |          |          |          |          |
|-----------------------------------|----------|----------|----------|----------|----------|----------|
|                                   |          | FY24E    |          |          | FY25E    |          |
| (₹ Crore)                         | Old      | New      | % Change | Old      | New      | % Change |
| Premiums earned - Net             | 81,182   | 78,710   | -3.0     | 96,182   | 91,253   | -5.1     |
| Total                             | 1,12,328 | 1,03,511 | -7.8     | 1,34,634 | 1,20,022 | -10.9    |
| Transfer to Shareholders' account | 1,778    | 2,479    | 39.5     | 1,867    | 2,480    | 32.8     |
| PAT                               | 1,703    | 1,858    | 9.1      | 1,992    | 2,125    | 6.7      |
| EV/Share                          | 517      | 514      | -0.5     | 593      | 588      | -0.9     |

Source: Company, ICICI Direct Research

| Exhibit 4: Assumption |       |       |       |       |
|-----------------------|-------|-------|-------|-------|
|                       | Cur   | rent  | Ear   | lier  |
|                       | FY24E | FY25E | FY24E | FY25E |
| NBP growth            | 14.3  | 20.6  | 15.6  | 20.6  |
| AUM growth            | 19.7  | 16.9  | 20.3  | 20.3  |
| EV Growth             | 11.7  | 14.3  | 14.4  | 14.8  |
| Comission ratio       | 3.7   | 3.7   | 3.6   | 3.6   |
| VNB Margin            | 29.6  | 30.0  | 29.6  | 30.0  |
| Conservation ratio    | 83.1  | 82.0  | 85.2  | 85.2  |
| Opearating RoEV       | 21.4  | 21.8  | 21.4  | 21.8  |

# Financial summary

| Exhibit 5: Policyholders Account            |         |         |          |          |
|---------------------------------------------|---------|---------|----------|----------|
| (₹ Crore)                                   | FY22    | FY23    | FY24E    | FY25E    |
| Premiums earned - Net                       | 58432.3 | 66581.0 | 78710.3  | 91252.8  |
| Income from Investments                     | 23568.0 | 13260.1 | 23639.4  | 27714.5  |
| Other income                                | 44.8    | 49.9    | 47.6     | 52.4     |
| Contribution from the Shareholders' account | 982.2   | 1707.5  | 1113.5   | 1002.1   |
| Total                                       | 83027.2 | 81598.5 | 103510.9 | 120021.8 |
| Commission                                  | 2084.1  | 2936.0  | 2906.1   | 3389.5   |
| Operating expenses                          | 2974.5  | 3409.5  | 4570.0   | 5298.3   |
| Benefits paid (Net)                         | 31339.8 | 30287.5 | 39049.1  | 46723.3  |
| Change in valuation of policy liabilities   | 43761.9 | 41003.1 | 53019.1  | 60471.8  |
| Others                                      | 101.7   | 197.3   | 8.0      | 8.0      |
| Provision for tax                           | 126.2   | 147.4   | 1079.1   | 1251.1   |
| Surplus/(deficit) after tax                 | 1807.4  | 2856.2  | 2879.4   | 2879.8   |
| Transfer to Shareholders' account           | 1732.4  | 2707.2  | 2479.4   | 2479.8   |

Source: Company, ICICI Direct Research

| Exhibit 6: Shareholders Account                 |        |        |        |        |
|-------------------------------------------------|--------|--------|--------|--------|
| (₹ Crore)                                       | FY22   | FY23   | FY24E  | FY25E  |
| Amounts transferred from Policyholders' account | 1732.4 | 2707.2 | 2479.4 | 2479.8 |
| Income from investments                         | 988.4  | 794.5  | 926.7  | 1051.8 |
| Total                                           | 2721   | 3502   | 3406   | 3532   |
| Expenses other than insurance                   | 157.0  | 37.2   | 24.7   | 19.5   |
| Contribution to Policyholders' account          | 982.2  | 1707.5 | 1447.5 | 1302.8 |
| Others                                          | 6.3    | 6.3    | 6.3    | 6.3    |
| Profit before Tax                               | 1560.8 | 1758.4 | 1933.9 | 2209.5 |
| Provision for tax                               | 54.8   | 37.9   | 75.9   | 84.4   |
| PAT                                             | 1506.0 | 1720.6 | 1858.0 | 2125.1 |

Source: Company, ICICI Direct Research

| Exhibit 7: Balance Sheet                 |        |        |        |        |
|------------------------------------------|--------|--------|--------|--------|
| (₹ Crore)                                | FY22   | FY23   | FY24E  | FY25E  |
| Sources of Funds                         |        |        |        |        |
| Share capital                            | 1000   | 1001   | 1000   | 1000   |
| Reserve and surplus                      | 10418  | 11924  | 12403  | 14226  |
| Credit/[debit] fair value change account | 204    | 93     | 308    | 308    |
| Networth                                 | 11622  | 13017  | 13711  | 15534  |
| Policyholders' funds                     | 255591 | 296569 | 362196 | 422668 |
| Total Liabilities                        | 268207 | 309587 | 378250 | 441045 |
| Applications of Funds                    |        |        |        |        |
| Shareholders' investments                | 10076  | 11209  | 13025  | 14757  |
| Policyholders' investments               | 112131 | 129870 | 171137 | 202439 |
| Asset held to cover linked liabilities   | 142625 | 163256 | 183626 | 212647 |
| Loans                                    | 363    | 389    | 503    | 568    |
| Fixed assets - net block                 | 527    | 522    | 780    | 874    |
| Net current assets                       | 2486   | 4342   | 9179   | 9760   |
| Total Assets                             | 268207 | 309587 | 378250 | 441045 |



| Exhibit 8: Key Ratios                                 |       |       |       |       |
|-------------------------------------------------------|-------|-------|-------|-------|
| (Year-end March)                                      | FY22  | FY23  | FY24E | FY25E |
| Valuation                                             |       |       |       |       |
| No. of Equity Shares (Crore)                          | 100.0 | 100.1 | 100.0 | 100.0 |
| Diluted EPS (₹)                                       | 15.1  | 17.2  | 18.6  | 21.3  |
| DPS (₹)                                               | 1.6   | 2.2   | 3.8   | 4.2   |
| BV (₹)                                                | 116.2 | 130.1 | 137.1 | 155.3 |
| EV per share                                          | 396   | 452   | 514   | 588   |
| P/E                                                   | 75.7  | 66.3  | 61.4  | 53.6  |
| P/BV                                                  | 9.8   | 8.8   | 8.3   | 7.3   |
| P/IEV                                                 | 2.9   | 2.5   | 2.2   | 1.9   |
| Efficiency Ratios (%)                                 |       |       |       |       |
| Commission expenses as a % of Gross Premium           | 3.5   | 3.6   | 3.7   | 3.7   |
| Management expenses incl commission as a % of Gross F | 9.6   | 9.2   | 9.4   | 9.4   |
| Return Ratios and capital (%)                         |       |       |       |       |
| Return on Net worth                                   | 13.7  | 10.8  | 16.2  | 15.9  |
| Operating RoEV                                        | 20.6  | 21.0  | 21.4  | 21.8  |
| Solvency Ratio                                        | 205   | 200   | 200   | 200   |
| Key Ratios (%)                                        |       |       |       |       |
| Conservation Ratio                                    | 83.3  | 85.0  | 83.1  | 82.0  |
| VNB Margin                                            | 21.7  | 29.7  | 29.6  | 30.0  |
| Surrender Ratio                                       | 4.6   | 5.0   | 5.0   | 5.1   |
| Benefits paid as a % of Opening Liability             | 14.8  | 12.5  | 12.6  | 12.8  |

# **RATING RATIONALE**

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%; Reduce: -15% to -5%;

Sell: <-15%



Pankaj Pandey

Head - Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk, ICICI Securities Limited, 1st Floor, Akruti Trade Centre, Road No 7, MIDC, Andheri (East) Mumbai – 400 093 research@icicidirect.com



### ANALYST CERTIFICATION

I/We, Kajal Gandhi, CA, Vishal Narnolia, MBA, and Pravin Mule, MBA, M.com. Analysts Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

## Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers is insultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or comanaging public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/beneficial ownership of one percent or more or other material conflict of interest various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.